PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-27.41%
Cash & equivalents declining -27.41% while Biotechnology shows -7.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-27.41%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of -6.40%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.07%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-28.37%
Current assets growth ≥ 1.5x the Biotechnology median of -5.24%. Joel Greenblatt sees a potential liquidity edge if well allocated.
1187.39%
PP&E growth ≥ 1.5x the Biotechnology median of 4.61%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
252.00%
≥ 1.5x the Biotechnology median of 3.27%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
≥ 1.5x the Biotechnology median of -2.28%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-8.53%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-29.62%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
12.29%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-3.44%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7668.72%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
13.42%
Above 1.5x Biotechnology median of 1.95%. Jim Chanos suspects an alarming rise in overall leverage.
2.97%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-3.03%
0.75-0.9x Biotechnology median of -3.77%. John Neff wonders if the firm lags peers in reinvested profits.
25.83%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-39.38%
≥ 1.5x Biotechnology median of -3.58%. Joel Greenblatt sees stronger equity growth vs. peers.
-17.83%
≥ 1.5x Biotechnology median of -2.28%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
499.58%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
37.73%
Above 1.5x Biotechnology median 14.26%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.